Drug and Therapeutics Bulletin 2007;45:5-8; doi:10.1136/dtb.2007.4515
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Exubera: inhaled insulin for diabetes

Relevant BNF section: 6.1.1.1

Over 2 million people in the UK have diabetes mellitus, of whom around 20% have type 1 and 80% type 2 disease.1 A key aim of treatment is to optimise glycaemic control to minimise symptoms, prevent complications and extend survival. To these ends, subcutaneous insulin is used to manage all patients with type 1 diabetes and some patients with type 2 diabetes. Another potential route of administering insulin is by inhalation. {blacktriangledown}Exubera (Pfizer), the first licensed inhaled insulin in the UK, is promoted as "the new look of insulin" and as maintaining "long-term glycaemic control". What does it offer in the management of patients with diabetes?






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2007 BMJ Publishing Group Ltd.